Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Health

Plitidepsin more efficient than remdesivir for reducing complications of COVID-19

Staff Writer
Staff Writer 1 year ago
Updated 2021/05/12 at 6:20 PM
Share
SHARE

Since the early stages of the COVID-19 pandemic in early-2020, many health professionals have attempted to treat complications associated with the disease using remdesivir. Although effective for some, a new study has discovered a drug treatment that is potentially more efficient.

Plitidepsin, an antiviral agent currently undergoing clinical testing, could be more efficient than remdesivir at treating the symptoms arising from SARS-CoV-2 infection. The drug is originally intended for use to treat multiple myeloma.

The new findings were based on clinical trial testing by a coalition of researchers in the United States, France, and Spain. Their study appeared in the peer-reviewed journal Science.

According to researchers, the drug’s primary action involves the inhibition of the protein eEF1A, a necessity for the SARS-CoV-2 strain to produce proteins for replication.

When comparing plitidepsin among infected samples of lung tissue, it was found to be significantly more efficient at eliminating the virus through eEF1A inhibition in comparison with remdesivir.

“Through the use of a drug resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A,” researchers wrote in their findings.

“We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19.”

Photo: Shutterstock

You Might Also Like

Study shows the likely outcomes of very preterm born children

Researchers find that stress accelerates immune aging

Study finds heavy drinkers are significantly more likely to smoke

Researchers suggest menthol cigarettes may raise the possibility of youth smoking and addiction

Childhood obesity epidemic may not be effectively mitigated through just diet and exercise

TAGGED: COVID-19, epidemiology, Plitidepsin, remdesivir
Staff Writer January 30, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Childhood trauma could hinder response to multiple sclerosis treatment later in life
Next Article Obesity may heighten the risk of developing Alzheimer’s disease

Recommended

Health

Study shows the likely outcomes of very preterm born children

1 Min Read
Health

Researchers find that stress accelerates immune aging

2 Min Read
Health

Study finds heavy drinkers are significantly more likely to smoke

1 Min Read
Health

Researchers suggest menthol cigarettes may raise the possibility of youth smoking and addiction

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?